Salarius Pharmaceuticals Announces Resumption of Clinical Trial for Seclidemstat and Azacitidine
Houston, Texas, February 3, 2025 – Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics for the treatment of genetically defined cancers and complex hematologic diseases, is pleased to announce that patient enrollment has resumed in the investigator-initiated Phase 1/2 clinical trial evaluating the combination of seclidemstat and azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) at the University of Texas MD Anderson Cancer Center (MDACC).
About the Clinical Trial
The randomized, open-label, multi-center study is listed as recruiting on clinicaltrials.gov with the trial identifier NCT04734990. The primary objective of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the combination of seclidemstat and azacitidine in patients with MDS and CMML. Seclidemstat is an investigational, oral, selective and reversible inhibitor of histone deacetylase 6 (HDAC6), while azacitidine is a standard-of-care, intravenous DNA methyltransferase inhibitor.
Impact on Patients
For patients diagnosed with MDS or CMML, this clinical trial offers a potential new treatment option. MDS and CMML are complex hematologic diseases characterized by ineffective bone marrow function, leading to anemia, neutropenia, and thrombocytopenia. Current treatment options include supportive care, chemotherapy, and bone marrow transplant. The combination of seclidemstat and azacitidine aims to enhance the therapeutic effect of azacitidine by targeting the epigenetic modifications that contribute to the development and progression of these diseases.
Impact on the World
The resumption of this clinical trial marks a significant step forward in the development of new treatments for MDS and CMML. Both diseases affect thousands of people worldwide, and current treatment options have limitations in terms of efficacy and side effects. The combination of seclidemstat and azacitidine could potentially improve the treatment landscape for these diseases, providing hope for patients and their families.
Conclusion
Salarius Pharmaceuticals’ announcement of the resumption of the clinical trial evaluating seclidemstat and azacitidine for the treatment of MDS and CMML represents an important milestone in the quest for new and effective therapies for these complex hematologic diseases. The potential combination of seclidemstat and azacitidine offers hope for patients and their families, and could significantly impact the treatment landscape for MDS and CMML. Stay tuned for updates on the progress of this trial and the potential benefits it may bring to the medical community.
- Salarius Pharmaceuticals announces resumption of clinical trial for seclidemstat and azacitidine
- Investigator-initiated Phase 1/2 study being conducted at MD Anderson Cancer Center
- Combination therapy targets epigenetic modifications in MDS and CMML
- Potential new treatment option for patients with complex hematologic diseases
- Significant step forward in the development of new treatments for MDS and CMML
